1
|
Wang W, Kothari-Talwar S, Roberts C, Lu Q, Lara N, Panchal R, Morais E, Chen YT, Qiao Y, Cui F. Estimating the prevalence of non-cervical human papillomavirus infection in mainland China (PROGRESS-Plus): protocol of a national cross-sectional study. BMJ Open 2023; 13:e065749. [PMID: 36731925 PMCID: PMC9896211 DOI: 10.1136/bmjopen-2022-065749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
INTRODUCTION Human papillomavirus (HPV) infection is the most common sexually transmissible infection worldwide. Although the prevalence of cervical HPV infection has been extensively reported in women worldwide, few epidemiological studies have examined the prevalence of non-cervical HPV infection among both women and men, especially in China. METHODS AND ANALYSIS PROGRESS-Plus is a national, multisite, cross-sectional study that aims to estimate the prevalence of non-cervical HPV infection in women and men aged 18-60 years residing in mainland China. More specifically, PROGRESS-Plus will estimate the prevalence rate of HPV DNA in oral samples from both women and men, and that of anogenital samples from men. The secondary study objectives are to (1) report the aforementioned prevalence rates by HPV genotype, age and geographical region, (2) examine the concordance (ie, prevalence of the same HPV genotype) between the oral and anogenital samples among men, (3) explore risk factors associated with oral (in both women and men) and anogenital (in men only) HPV infection and (4) describe study participants' health-related quality of life, health behaviour, sexual behaviour and health status. ETHICS AND DISSEMINATION The study protocol and all required documents have been submitted for review and approval to the Independent Ethics Committees of all the participating sites. All participants will provide their written informed consent on study entry, and all the recorded data will be treated as confidential.
Collapse
Affiliation(s)
- Wei Wang
- Merck & Co Inc, Rahway, New Jersey, USA
| | | | | | - Qingbin Lu
- School of Public Health, Peking University, Beijing, China
| | | | | | | | | | - Youlin Qiao
- Cancer Epidemiology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Fuqiang Cui
- Peking University Health Science Centre, Beijing, China
| |
Collapse
|
2
|
Buenconsejo L, Kothari-Talwar S, Yee K, Kulkarni A, Lara N, Roset M, Giuliano AR, Garland S. Estimating the burden of illness related to genital warts in the Philippines: a nationally representative cross-sectional study. Infect Agent Cancer 2019; 14:26. [PMID: 31624494 PMCID: PMC6781391 DOI: 10.1186/s13027-019-0240-y] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2019] [Accepted: 08/22/2019] [Indexed: 11/10/2022] Open
Abstract
Background This study estimated genital warts prevalence, genital-warts-related healthcare resource use and costs, and self-reported human-papillomavirus-related psychosocial impact among male and female patients aged 18-60 years in the Philippines. Methods Prevalence was estimated using daily logs numbering genital warts patients treated by participating physicians in 4 Philippine regions over a 5-week period (09JUL2011-24SEP2012). Physicians also completed a survey assessing patient referral patterns, healthcare resource use, treatment, and follow-up care. Psychosocial impact was estimated using the human papillomavirus impact profile and the EQ-5D questionnaires. HIP and EQ-5D scores were compared according to the presence of GW (males) and HPV disease (females). CECA scores were also compared by gender and age groups. Results Overall genital warts prevalence was estimated at 4.78% (95% confidence interval [CI]: 4.58-4.98%) for men and women aged 18-60 years. Genital warts prevalence was 3.39% (95% CI: 3.13-3.65%) and 8.0% (95% CI: 7.69-8.31%) among women and men, respectively. Prevalence estimates were highest in infectious disease specialist practices 18.67% (95% CI: 18.66-18.69%). Two thirds of the 233 (69.14%) male and 166 (67.20%) female patients were newly-diagnosed genital warts cases. Median costs for genital warts diagnosis and treatment reached 7121 and 7000 Philippine pesos among men and women, respectively. In the Cuestionario Específico para Condiloma Acuminado questionnaire, no statistically significant differences between patients were observed. In the EQ-5D questionnaire, male genital warts patients reported lower mean visual analogue scale scores than those without genital warts (78.20 vs 86.34, p < 0.0001). Mean visual analogue scale score values and utility values were lower for women with human-papillomavirus-related diseases than those without (77.98 vs 78.93, and 0.84 vs 0.88, respectively). Conclusions Genital warts is prevalent in the Philippines; more than 60% of cases were newly diagnosed, contributing to high genital-warts-related healthcare resource costs. Diagnosis of genital warts and human papillomavirus negatively impacted psychosocial indices such as patient well-being and health-related quality of life.
Collapse
Affiliation(s)
| | | | - Karen Yee
- 3Cubist Pharmaceuticals, Lexington, MA USA
| | | | | | | | - Anna R Giuliano
- 5Center for Infection Research in Cancer (CIRC) at Moffitt Cancer Center, Tampa, FL USA
| | | |
Collapse
|
3
|
Tsai TF, Kothari-Talwar S, Yee K, Kulkarni A, Lara N, Roset M, Giuliano AR, Garland SM. Estimating the burden of genital warts in Taiwan. Sex Health 2019; 14:485-491. [PMID: 28968509 DOI: 10.1071/sh17013] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2017] [Accepted: 05/21/2017] [Indexed: 01/11/2023]
Abstract
Background This study aimed to estimate the prevalence of genital warts in Taiwan among those seeking healthcare, as well as genital-warts-related healthcare resource use and costs, and self-reported genital-warts-related psychosocial impact. METHODS Genital warts prevalence estimates were extracted from a daily record of patients examined from 31 October 2011 to 4 May 2012 by 67 physicians in Taiwan. Physicians recorded the total number of patients and genital warts patients seen daily for 2 weeks. These physicians also completed a survey regarding healthcare resource use, treatment, follow-up care, and referral patterns. Patient psychosocial impact was estimated using a self-administered survey. RESULTS The overall prevalence of genital warts in Taiwan was estimated at 1.1%, with a higher prevalence among men. A total of 146 genital warts case patients were included in the study (76 men, 70 women). Median costs for diagnosis and treatment were US$222 for male and US$351.8 for female patients. Male genital warts subjects reported a negative psychosocial impact on their well-being and health-related quality of life - psychosocial impact results are reported in the Supplementary Material file. CONCLUSIONS Genital warts prevalence was higher among male patients; female patients incurred higher costs. Among men, genital warts had a negative psychosocial impact on well-being and health-related quality of life.
Collapse
Affiliation(s)
- Tsen-Fang Tsai
- National Taiwan University Hospital, No. 7, Zhongshan S Road, Zhongzheng District, Taipei City, 100, Taiwan
| | | | - Karen Yee
- Cubist Pharmaceuticals, 65 Hayden Avenue, Lexington, MA 02421, USA
| | - Amit Kulkarni
- Merck & Co. Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA
| | - Nuria Lara
- Intercontinental Marketing Services Health, Carrer de Provença, 392, 08025 Barcelona, Spain
| | - Montserrat Roset
- Intercontinental Marketing Services Health, Carrer de Provença, 392, 08025 Barcelona, Spain
| | - Anna R Giuliano
- Center for Infection Research in Cancer at Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL 33612, USA
| | - Suzanne M Garland
- Royal Women's Hospital, 20 Flemington Road, Parkville, Vic. 3052, Australia
| |
Collapse
|
4
|
Lee TS, Kothari-Talwar S, Singhal PK, Yee K, Kulkarni A, Lara N, Roset M, Giuliano AR, Garland SM, Ju W. Cross-sectional study estimating the psychosocial impact of genital warts and other anogenital diseases in South Korea. BMJ Open 2019; 9:e025035. [PMID: 30898815 PMCID: PMC6475443 DOI: 10.1136/bmjopen-2018-025035] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/04/2022] Open
Abstract
OBJECTIVES To estimate self-reported human papillomavirus (HPV) disease-related psychosocial impact among male and female patients in South Korea. DESIGN In this multicentre cross-sectional study, psychosocial impacts were estimated using a one-time survey capturing HPV Impact Profile (HIP) results, CuestionarioEspecifico en Condilomas Acuminados (CECA; in Spanish)-'Specific questionnaire for Condylomata Acuminata' and the EuroQol-5 Dimension (EQ-5D) surveys. Student's t-tests or Mann-Whitney U tests were used for continuous comparisons; χ2 or Fisher's exact tests were applied for categorical comparisons. SETTING 5098 clinics throughout Seoul, Busan, Daegu, Kwangju and Daejeon (South Korea). PARTICIPANTS Patients with and without genital warts (GW) (males) and selected HPV diseases (females) visiting primary care physicians, obstetricians/gynaecologists, urologists and dermatologists with 2-30 years experience. RESULTS Of 150 male and 250 female patients, HIP scores showed 85.3% of male patients with GW and 32.0% without reported moderate psychological impact (p<0.0001). In categorised total scores, 88.5% of female patients with and 66.0% without selected HPV-related diseases reported moderate or high psychological impacts (p=0.0004). In the CECA questionnaire, male patients had mean (SD) scores of 10.51 (3.79) in 'emotional health' and 15.90 (6.13) in 'sexual activity'. Female patients with GW reported lower scores in both dimensions with mean scores of 7.18 (4.17) in 'emotional health' and 10.97 (5.80) in 'sexual activity' (p<0.0001), indicating worse health-related quality of life (HRQoL). For the EQ-5D, male patients with GW reported lower mean Visual Analogue Scale (VAS) scores than those without (75.1 vs 81.13, p<0.0135). Mean VAS score and utility values were lower for females with HPV-related diseases than those without (72.18 vs 76.86 and 0.90 vs 0.94, respectively). CONCLUSION In South Korea, GW in men and HPV-related diseases in women negatively impact patient well-being and HRQoL scores. Among women, those with GW suffered a greater psychosocial impact than those with other selected HPV-related diseases.
Collapse
Affiliation(s)
- Taek Sang Lee
- Department of Obstetrics and Gynecology, SMG-SNU Boramae Medical Center, Seoul, South Korea
| | | | | | - Karen Yee
- Cubist Pharmaceuticals Inc, Lexington, Massachusetts, USA
| | | | - Nuria Lara
- Real World Evidence Solutions, IQVIA, Barcelona, Spain
| | | | - Anna R Giuliano
- Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Suzanne M Garland
- Microbiology and Infectious Diseases Department, The Royal Women’s Hospital, Parkville, Victoria, Australia
| | - Woong Ju
- School of Medicine, Ewha Womans University, Seoul, South Korea
| |
Collapse
|
5
|
Khopkar US, Rajagopalan M, Chauhan AR, Kothari-Talwar S, Singhal PK, Yee K, Kulkarni A, Lara N, Roset M, Giuliano AR, Garland SM. Prevalence and Burden Related to Genital Warts in India. Viral Immunol 2018; 31:346-351. [PMID: 29717924 DOI: 10.1089/vim.2017.0157] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The prevalence of genital warts (GW) and self-reported human papillomavirus (HPV) as well as disease-related psychosocial impact among male and female patients aged 18-60 years in India were assessed. GW prevalence was estimated using a 2-week daily log of patients examined from June 7-September 22, 2011 by 200 participating physicians in 6 regions of India. Psychosocial impact was estimated using one-time, self-administered surveys, including HPV Impact Profile (HIP), Cuestionario Específico para Condiloma Acuminado ([Spanish] CECA; "Specific questionnaire for Condylomata Acuminata") and EuroQol-5 Dimension survey. T-tests or Mann-Whitney U-tests were used for continuous comparisons and Chi-square or Fisher exact tests were applied for categorical comparisons. Overall GW prevalence in India was estimated at 1.07% (95% confidence interval = 0.97-1.17) and was higher among men than women. Regional prevalence ranged from high in Delhi (2.17%) to low in Bangalore (0.40%). Patients aged 25-29 years had the highest GW prevalence (1.42%). GW patients were most often newly diagnosed (74.07%). Among those with existing GW, 56.24% were recurrent, and 43.76% were resistant. According to total HIP scores, 55.4% of male GW patients and 20.0% of those without GW reported moderate psychological impact (p < 0.0001). HIP scores among women revealed that patients with abnormal Papanicolaou (Pap) test results (34.3%), precancerous lesions (46.2%), external GW (48.0%), and those without HPV-related disease (18.5%) reported moderate psychological impact (p = 0.0089) (Psychosocial impact results are reported in the Supplementary Data ). Estimated national GW prevalence, diagnosis, and treatment costs in India were higher for men than for women. GW in men and HPV infection in women had a negative psychosocial impact on well-being and health-related quality of life (HRQoL) scores, especially among women diagnosed with GW and precancerous lesions compared to those with other selected HPV-related diseases. Despite its limitations, this study provides an estimation of GW data in India not previously available.
Collapse
Affiliation(s)
- Uday S Khopkar
- 1 Department of Dermatology and Venereology, Seth GS Medical College and KEM Hospital , Mumbai, India
| | | | - Anahita R Chauhan
- 3 Department of Obstetrics and Gynecology, Seth GS Medical College and King Edward Memorial Hospital , Mumbai, India
| | | | | | - Karen Yee
- 5 Cubist Pharmaceuticals , Lexington, Massachusetts
| | | | | | | | - Anna R Giuliano
- 7 Center for Infection Research in Cancer (CIRC), Moffitt Cancer Center , Tampa, Florida
| | | |
Collapse
|
6
|
Lee TS, Kothari-Talwar S, Singhal PK, Yee K, Kulkarni A, Lara N, Roset M, Giuliano AR, Garland SM, Ju W. A cross-sectional study estimating the burden of illness related to genital warts in South Korea. BMJ Open 2017; 7:e014217. [PMID: 28674130 PMCID: PMC5734288 DOI: 10.1136/bmjopen-2016-014217] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
OBJECTIVES Estimate the prevalence of genital warts (GW) and GW-related healthcare resource use and costs among male and female patients seeking treatment in South Korea. DESIGN To estimate GW prevalence, physicians in five major South Korean regions recorded daily logs of patients (n=71 655) seeking care between July 26 and September 27, 2011. Overall prevalence estimates (and 95% CIs) were weighted by the estimated number of physicians in each specialty and the estimated proportion of total patients visiting each specialist type. Healthcare resource use was compared among different specialties. Corresponding p values were calculated using Mann-Whitney U tests. SETTING The database covers 5098 clinics and hospitals for five major regions in South Korea: Seoul, Busan, Daegu, Gwangju and Daejeon. PARTICIPANTS Primary care physicians (general practice/family medicine), obstetricians/gynaecologists, urologists and dermatologists with 2-30 years' experience. RESULTS The estimated overall GW prevalence was 0.7% (95% CI 0.7% to 0.8%). Among women, GW prevalence was 0.6% (95% CI 0.6% to 0.7%); among men prevalence was 1.0% (95% CI 0.9% to 1.0%), peaking among patients aged 18-24 years. Median costs for GW diagnosis and treatment for male patients were US$58.2 (South Korean Won (KRW) ₩66 857) and US$66.3 (KRW₩76 113) for female patients. CONCLUSIONS The estimated overall GW prevalence in South Korea was 0.7% and was higher for male patients. The overall median costs associated with a GW episode were higher for female patients than for male patients.
Collapse
Affiliation(s)
- Taek Sang Lee
- Obstetrics and Gynecology, SMG-SNU Boramae Medical Center, Seoul, South Korea
| | | | - Puneet K Singhal
- Outcomes Research, Merck & Co., Inc., Kenilworth, New Jersey, USA
| | - Karen Yee
- Outcomes Research, Cubist Pharmaceuticals, Lexington, Massachusettes, USA
| | - Amit Kulkarni
- Outcomes Research, Merck & Co., Inc., Kenilworth, New Jersey, USA
| | - Nuria Lara
- Outcomes Research, Intercontinental Marketing Services (IMS) Health, Barcelona, Spain
| | - Montserrat Roset
- Outcomes Research, Intercontinental Marketing Services (IMS) Health, Barcelona, Spain
| | - Anna R Giuliano
- Research, Center for Infection Research in Cancer (CIRC) at Moffitt Cancer Center, Tampa, Florida, USA
| | | | - Woong Ju
- Obstetrics and Gynaecology, Ewha Woman's University, School of Medicine, Seoul, South Korea
| |
Collapse
|
7
|
Spiegel BM, Roberts L, Mody R, Harding G, Kothari-Talwar S, Kahrilas PJ, Camilleri ML, Dabbous O, Revicki DA. The development and validation of a Nocturnal Gastro-oesophageal Reflux Disease Symptom Severity and Impact Questionnaire for adults. Aliment Pharmacol Ther 2010; 32:591-602. [PMID: 20528826 DOI: 10.1111/j.1365-2036.2010.04385.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND Current questionnaires for assessing gastro-oesophageal reflux disease (GERD) symptoms are limited in their ability to capture nocturnal symptoms. AIM To develop and validate an instrument, the Nocturnal Gastro-oesophageal Reflux Disease Symptom Severity and Impact Questionnaire (N-GSSIQ), to assess severity and impact of nocturnal GERD symptoms. METHODS Two focus groups and 16 cognitive debriefing interviews were conducted among GERD patients to identify key issues about nocturnal symptoms. A draft instrument was tested in 196 patients at 11 clinics in the US to evaluate psychometric properties. Exploratory factor and item response theory analyses were conducted to finalize items and subscales. Internal consistency reliability, reproducibility and construct validity were examined. RESULTS Mean age was 45 (s.d. = 13.8) years; 76% were female and 68% were Caucasian. Patient-rated severity was mild-moderate for 69% of participants; 48% reported symptoms on two to three nights the past week. The final questionnaire includes 20 items and three subscales: Nocturnal GERD Symptoms, Morning Impact of Nocturnal GERD and Concern about Nocturnal GERD. The subscales demonstrated internal consistency reliability (Cronbach's alpha 0.84-0.94) and were significantly correlated with similar measures and disease severity (0.41-0.81; P < 0.0001). CONCLUSION The results support the reliability and validity of the N-GSSIQ as a measure of severity, morning impact and concern about nocturnal GERD.
Collapse
Affiliation(s)
- B M Spiegel
- Internal Medicine, Digestive Diseases Division, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|